Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
105P - Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected non-small cell lung cancer (ID 358)
12:30 - 13:00 | Author(s): Y. Tanaka
Cisplatin-based adjuvant chemotherapy improved overall survival and relapse free survival (RFS) of patient with completely resected stage II and III non-small cell lung cancer (NSCLC). However, the adverse effects of cisplatin-based regimen have not satisfied both patients and clinicians yet, and most of patients have to be hospitalized during chemotherapy. Recently, pemetrexed regimen as adjuvant chemotherapy was reported to result less toxicity than vinorelbine. Additionally, safety of short hydration method for cisplatin administration has been reported. The aim of our study was to investigate the feasibility of pemetrexed plus cisplatin with short hydration as adjuvant chemotherapy in patients with completely resected NSCLC.
21 completely resected non-squamous NSCLC patients with pathological stage IIA, IIB, and IIIA were enrolled. Adjuvant chemotherapy was started between four and eight weeks after surgery, and consisted of 4 cycles of pemetrexed (500 mg/m) plus cisplatin (75 mg/m) every 3 weeks with short hydration. The first cycle of each patient was administered with hospitalization, and the others were in outpatient clinic in principle. The primary endpoint was the completion rate of treatment, and secondary endpoints included toxicity, two-year RFS rate, and outpatient treatment rate (rate of outpatient chemotherapy at second cycle).
Patients were median age 66 years (range 57 to 75) and gender 57% male/43% female. All cases were adenocarcinoma. Pathological stages were IIA 52%, IIB 19%, and IIIA 29%. 81% of patients received 4 cycles of therapy as scheduled. Only 1 patient needed decrease of chemotherapy dose and the reason was prolonged anorexia. No grade 3 or 4 hematologic toxicity was observed. Except for one grade-3 pulmonary thromboembolism and two grade-3 anorexia the adverse events were relatively mild. Increased serum creatinine was observed only one patient (grade 1). Outpatient treatment rate was 90%. Two-year RFS rate was 59%.
Adjuvant pemetrexed and cisplatin chemotherapy with short hydration for resected non-squamous NSCLC is safety and able to be performed in outpatient basis.
Clinical trial identification:
Legal entity responsible for the study:
Has not received any funding
All authors have declared no conflicts of interest.